Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Siponimod effects on MRI and immunological markers in progressive multiple sclerosis
2020-005947-22Phase 4Active
- Sponsor
- Azienda Ospedaliera Universitaria Integrata Verona
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of siponimod in multiple sclerosis (MS) and secondary-progressive multiple sclerosis (SPMS), sponsored by Azienda Ospedaliera Universitaria Integrata Verona. Primary endpoint: Change in susceptibility of paramagnetic rim lesions. Started Oct 2021; status: active.
02
Drugs
siponimod
03
Conditions
multiple sclerosis (MS)secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on 2020-005947-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005947-22.